- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Stellar Biotechnologies, Inc. (Stellar) is pleased to announce that it has agreed to complete a CDN$ 1.05M private placement subject to acceptance by the TSX Venture Exchange, and, also, the cancellation of 1,661,241 shares of the Company's outstanding common stock.
Stellar Agrees to Complete Financing
Subject to acceptance by the TSX Venture Exchange, Stellar has agreed to complete its non-brokered, private placement of 3,000,000 Units at CDN$ 0.35 per Unit for CDN$ 1,050,000, with a single, long-term, strategic investor for the specific purpose of advancing a new product line, sought after by our customers and potential customers, that was not envisioned in the previous budget.
Each Unit is composed of one common share and one 1/2 warrant, each warrant for purchase of a common share at $0.50 until eighteen months from the issuing of the shares upon completion. The shares issued in the Private Placement are subject to a 4 month and 1 day hold period from that date, and a finder's fee will be payable subject to the regulations of the TSX Venture Exchange.
Stellar Cancels 1,661,241 of Outstanding Shares
In a pre-arranged deal, Stellar cancelled 1,661,241 common shares on payment by the Company of approximately US$ 0.075 (7.5 cents)/share. Stellar believes the retirement of these shares benefits the Company and all shareholders by reducing the number of outstanding shares and lowering dilution.
Darrell Brookstein, Director & Executive VP, Business Development & Finance of Stellar, said, "We were able to retire shares to our treasury at a steep discount to the market, and, pending acceptance by the Exchange, sell Units to a long-term, significant shareholder with strong coastal development experience in an area that is complementary to our southern California location. We view the ability to raise this additional capital now as significant -- advancing and building on our new market opportunity, while forging a strong relationship with a committed financier and shareholder."
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.
Statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information, please click here
Business Development & Finance
Copyright © MarketwireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Leading Advanced Materials Manufacturer Pixelligent Closes $10.4 Million in Funding: Capital Will Boost Capacity for North American Manufacturing, Drive Asian Expansion, and Continue Innovation in Solid State Lighting and OLED Display Applications August 16th, 2016
Harris & Harris Group to Host a Shareholder Update Call, Including a Presentation by One of Its Precision Health and Medicine Portfolio Companies, Muses Labs, Inc., on August 23, 2016 August 16th, 2016
Nanoparticles that speed blood clotting may someday save lives August 23rd, 2016
Curbing the life-long effects of traumatic brain injury August 19th, 2016